Skip to content

Study · Systematic review · 2026

5 results

Cardiovascular Outcomes With Tirzepatide Versus GLP-1 Receptor Agonists in Overweight or Obesity: A Systematic Review and Meta-Analysis.

Silva JPMRJ, Nogueira BV, Sartori DL, da Silva JRC, Sciota LBA, de Mendonça Bisneto OI, Gomes WF

Diabetes, obesity & metabolism6 Jul 2026Cited by 1 (Europe PMC)

PMID42410309 (opens in a new tab)PMCIDPMC13449074 (opens in a new tab)DOI10.1111/dom.71051 (opens in a new tab)PepBankPUB-42410309
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults with overweight or obesity, the all-cause mortality estimate for tirzepatide versus GLP-1 receptor agonists was directionally lower but its confidence interval included 1.

    In plain wordsIn adults with overweight or obesity, tirzepatide showed no clear difference in deaths from any cause compared with other GLP-1 drugs.

    Peptide
    Tirzepatide
    Outcome
    No significant changeAll-cause mortality
    Study

    n: not reported in source

    Comparator
    GLP-1 receptor agonists
    Analysis
    Secondary
    Outcome group
    Mortality · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    HR
    0.9 ratio
    all-cause mortality

    Source sentences

    Summary
    Effect estimates were directionally consistent across secondary outcomes, including all-cause mortality (HR 0.90, 95% CI 0.79-1.02)
    1 context sentence
    Summary · context
    Eight studies (one randomized and seven observational) including 323 439 patients were analysed.
  2. 02HumanSystematic reviewEfficacy outcome

    In adults with overweight or obesity, the cardiovascular mortality estimate for tirzepatide versus GLP-1 receptor agonists was directionally lower but not statistically significant.

    In plain wordsIn adults with overweight or obesity, tirzepatide showed no clear difference in heart-related deaths compared with other GLP-1 drugs.

    Peptide
    Tirzepatide
    Outcome
    No significant changeCardiovascular mortality
    Study

    n: not reported in source

    Comparator
    GLP-1 receptor agonists
    Analysis
    Secondary
    Outcome group
    Mortality · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    HR
    0.88 ratio
    cardiovascular mortality

    Source sentences

    Summary
    cardiovascular mortality (HR 0.88, 95% CI 0.76-1.00).
    1 context sentence
    Summary · context
    Eight studies (one randomized and seven observational) including 323 439 patients were analysed.
  3. 03HumanSystematic reviewEfficacy outcome

    In an exploratory subgroup of patients with type 2 diabetes, tirzepatide was associated with lower all-cause mortality than GLP-1 receptor agonists.

    In plain wordsIn people with type 2 diabetes, tirzepatide was linked to fewer deaths from any cause than other GLP-1 drugs, in an exploratory analysis.

    Peptide
    Tirzepatide
    Outcome
    DecreaseAll-cause mortality in type 2 diabetes subgroup
    Study

    n: not reported in source

    Comparator
    GLP-1 receptor agonists
    Analysis
    Exploratory
    Outcome group
    Mortality · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    HR
    0.85 ratio
    all-cause mortality, type 2 diabetes

    Source sentences

    Summary
    In exploratory subgroup analyses, patients with type 2 diabetes showed lower estimated risks of all-cause mortality (HR 0.85, 95% CI 0.76-0.94) and heart failure (HR 0.75, 95% CI 0.58-0.97).
    1 context sentence
    Summary · context
    Eight studies (one randomized and seven observational) including 323 439 patients were analysed.
  4. 04HumanSystematic reviewEfficacy outcome

    In an exploratory subgroup of patients with type 2 diabetes, tirzepatide was associated with a lower estimated risk of heart failure than GLP-1 receptor agonists.

    In plain wordsIn people with type 2 diabetes, tirzepatide was linked to a lower risk of heart failure than other GLP-1 drugs, in an exploratory analysis.

    Peptide
    Tirzepatide
    Outcome
    DecreaseHeart failure in type 2 diabetes subgroup
    Study

    n: not reported in source

    Comparator
    GLP-1 receptor agonists
    Analysis
    Exploratory
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    HR
    0.75 ratio
    heart failure, type 2 diabetes

    Source sentences

    Summary
    In exploratory subgroup analyses, patients with type 2 diabetes showed lower estimated risks of all-cause mortality (HR 0.85, 95% CI 0.76-0.94) and heart failure (HR 0.75, 95% CI 0.58-0.97).
    1 context sentence
    Summary · context
    Eight studies (one randomized and seven observational) including 323 439 patients were analysed.
  5. 05HumanSystematic reviewEfficacy outcome

    In adults with overweight or obesity, tirzepatide was not associated with a statistically significant reduction in MACE compared with GLP-1 receptor agonists, with substantial heterogeneity.

    In plain wordsIn adults with overweight or obesity, tirzepatide did not clearly lower serious heart events more than other GLP-1 drugs.

    Peptide
    Tirzepatide
    Outcome
    No significant changeMajor adverse cardiovascular events (MACE)
    Study

    n: not reported in source

    Comparator
    GLP-1 receptor agonists
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    HR
    0.85 ratio
    MACE

    Source sentences

    Summary
    Tirzepatide was not associated with a statistically significant reduction in major adverse cardiovascular events (MACE) compared with GLP-1 receptor agonists (HR 0.85, 95% CI 0.70-1.04; I 2 = 90.4%).
    1 context sentence
    Summary · context
    Eight studies (one randomized and seven observational) including 323 439 patients were analysed.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.